Published in Gene Therapy Weekly, August 30th, 1999
Under the agreement, EntreMed's angiostatin and endostatin genes will be combined with Cell Genesys' proprietary adenoviral and adeno-associated viral (AAV) gene delivery systems in preclinical studies designed to assess whether the gene therapy can treat tumors by inhibiting their blood supply. The two companies will consider a potential business relationship based on the results of the studies performed under this collaboration.
Angiostatin and endostatin are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.